Summary

This is our report on a major rule promulgated by the Department of Health and Human Services. It was published in the Federal Register as a final rule on August 29. Whichever is later. 5 U.S.C. 801(a)(3)(A). The rule was published on August 29. Was received by Congress on September 4. The rule does not have the required delay in its effective date. Enclosed is our assessment of the CMS's compliance with the procedural steps required by section 801(a)(1)(B)(i) through (iv) of title 5 with respect to the rule. If you have any questions about this report. The official responsible for GAO evaluation work relating to the subject matter of the rule is William Scanlon. TIME LIMITATION ON PRICE RECALCULATIONS AND RECORDKEEPING REQUIREMENTS UNDER THE DRUG REBATE PROGRAM" (RIN: 0938-AM20) (i) Cost-benefit analysis CMS estimates that the final rule will save $90 million annually over the next 5 years ($50 million in federal savings and $40 million in state savings). (ii) Agency actions relevant to the Regulatory Flexibility Act.